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Abstract
Background: Immune thrombocytopenia (ITP) in dogs is analogous to that in humans. Romiplostim, a novel
thrombopoietin receptor (TPO-R) agonist, is currently used for the treatment of refractory ITP in humans, but not in
dogs. Here, we describe the response to romiplostim in five dogs with refractory ITP. Five dogs with severe and
refractory ITP (three primary and two secondary) received romiplostim subcutaneously. Four dogs were administered
3–5 μg/kg and one dog received 10–13 μg/kg body weight once weekly.
Results: Romiplostim was well-tolerated and administration was associated with an increase in platelet counts in all
five dogs. Four of the five dogs entered remission and relapses were not observed over a follow-up period of 3–10
months.
Conclusions: Romiplostim is effective in the treatment of ITP in dogs at least as well as in humans. This finding may
help to develop and use new therapeutics for ITP in dogs and humans.
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Background
Immune thrombocytopenia (ITP) is a well-characterized
autoimmune bleeding disease in humans that is accom-
panied by the immune-mediated destruction of platelets
and impaired thrombopoiesis [1–4]. Comparable to
humans, dogs develop ITP spontaneously [5] or second-
ary following infectious or neoplastic diseases [6–8]. Dif-
ferential diagnosis of ITP in both species is based on the
exclusion of known causes or underlying diseases [5, 9].
The current treatment options for ITP in humans and
dogs are largely identical. Corticosteroid administration
is generally accepted as the first-line treatment option in
affected human patients and dogs [10, 11]. However, the
effect of steroids is not predictable in a single patient
[12]. Approximately two-thirds of human patients
achieve a complete or partial response with corticoste-
roids, although a high proportion of patients relapse and
require alternative therapy [13]. Similarly, steroid treat-
ment may remain ineffective and may result in severe
adverse reactions in dogs [8, 10, 14–16].
A second line therapy in dogs is not well-defined and
may include platelet transfusions and high dose intraven-
ous immunoglobulins (IVIgG) for acute management, or
vincristine, azathioprine, mycophenolate mofetil, cyclo-
phosphamide, cyclosporine, danazol, leflunomide, and
ultimately splenectomy for long-term management and in
cases of relapse or refractory ITP [8, 10, 16–19]. These
treatment options are not performed analogously and
there are no generally accepted guidelines on when they
should be used [16]. The rates of relapse and mortality in
dogs range between 9 % and 43 % [8, 10, 15, 18, 20–22].
During the last decade, significant new aspects regard-
ing the pathogenesis and treatment of ITP in humans
have been highlighted. Patients with ITP have been
found to have increased platelet destruction due to auto-
antibodies and an impaired thrombopoiesis in the bone
marrow [3, 23]. Consequently, two thrombopoietin re-
ceptor (TPO-R) agonists, romiplostim and eltrombopag,
have been shown to be effective in the treatment of
human ITP [24]. Romiplostim is a 59 kDa peptibody that
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binds to the extracellular domain of TPO-R on megakar-
yocytes and platelets, activates the receptor, and in-
creases platelet counts [25]. In contrast, eltrombopag is
a small molecule with a molecular weight of 442 Da,
and is a non-peptide TPO-R agonist that selectively
binds to the transmembrane domain of the TPO-R and
increases platelet counts [26]. The safety and efficiency
of TPO agonists in the treatment of ITP has been previ-
ously studied in well-designed controlled and random-
ized clinical trials. Eltrombopag is administered orally at
a dosage ranging between 25 and 75 mg/d, and 1–10 μg/kg
romiplostim is administered subcutaneously once weekly
[22, 27–29]. Treatment with TPO agonists is usually indi-
cated in patients with refractory ITP and in patients who
do not adequately respond to standard therapy [22, 27].
Dogs with therapy refractory ITP are at a high risk of
life-threatening bleeding. In such cases, there are no
alternative therapeutic options, and affected dogs either
die or are euthanized due to thrombocytopenia [5]. As
ITP in dogs is largely analogous to ITP in humans, we
questioned whether human TPO agents such as the Food
and Drug Administration (FDA) approved human TPO-R
agonists can be used as a new therapeutic measure in dogs
with ITP that cannot be controlled by standard therapy.
Methods
Five dogs with primary or secondary ITP were admitted
to the Small Animal Clinic at the Freie Universität Berlin
between 10/2014 and 6/2015 and were treated with
romiplostim. Inclusion criteria were diagnosed primary
or secondary ITP based on complete medical records,
platelet counts < 150,000/μl and a positive platelet-
bound antibody test. Primary ITP was only diagnosed, if
there was no evidence of any other underlying disease or
cause which might have triggered platelet destruction. In
presence of an additionally positive direct Coombs’ test,
Evans’ syndrome was diagnosed. Discrimination of pri-
mary and secondary forms of ITP was based on the
complete diagnostic work-up that comprised of a
complete blood count, blood smear evaluation, testing
for erythrocyte agglutination, clinical chemistry, coagula-
tion panel, diagnostic imaging including thoracic and ab-
dominal radiography and ultrasonography, direct and
indirect tests for infectious diseases, and immunological
testing [7, 8]. The dogs had been pre-treated with pred-
nisolone and adjunctive immunosuppressive drugs and
were either non-responders or were readmitted due to a
relapse. A response to therapy (complete remission) was
defined as an increase of the platelet count to ≥ 150,000/
μl. A relapse was defined as a decrease of the platelet
count below 150,000/μl after the value had already been
within reference range. A dog was classified as non-
responder when, the platelet counts did not increase or
did not reach values above 150.000/μl.(references) The
dosage for each dog was extrapolated from human data,
and was dependent on the clinical responses [30]. Con-
sent from the owners was obtained. Romiplostim is li-
censed in human medicine and a comparable product is
not available in veterinary medicine. Therefore this drug
can be used in veterinary medicine without approval of
an ethics committee. Moreover all the dogs were treated
using standard therapy (best practice of veterinary care)
first before using this novel agent.
Results
Depending on the availability of romiplostim and the se-
verity of ITP in affected dogs, treatment was initially com-
menced with a dosage of 3–5 μg/kg per week. Prior to
treatment with romiplostim, all dogs had underwent con-
ventional treatment (Tables 1 and 2) and had experienced
one or more relapses. Treatment was either ineffective or
was discontinued to avoid the development of severe side
effects (e.g. in the case of ehrlichiosis). Administration of
romiplostim resulted in an increase of platelet counts
within 3–6 days following the commencement of treat-
ment in 4 of the 5 treated dogs (Table 2). The remaining
dog suffered from ehrlichiosis and hepatopathy, and did
not respond to the administration of 5.3 μg/kg of romi-
plostim. Bone marrow examination revealed the presence
of numerous megakaryocytes. A dose escalation was
attempted after the following 2 months and the dog re-
ceived first 13 μg/kg and then 10 μg/kg after one week.
Simultaneously, prednisolone was re-administered due to
the deterioration of hepatopathy. One week after the sec-
ond injection, an increase in platelet counts was observed
(Table 2). We report here a mean length of treatment of
13.8 (min. 3, max. 35 and median 11 weeks) weeks, which
were varying for each individual dog. None of the treated
dogs developed any side effects. Concomitant therapy with
other drugs was gradually reduced and halted in three of
the dogs when the platelet count was stabilized. Interest-
ingly, none of the five dogs relapsed during observation.
Moreover, the initially given dose of romiplostim could be
reduced in four cases (Table 2).
Discussion
ITP is the most common cause of severe thrombocytopenia
in dogs [31]. Corticosteroids are considered as the corner-
stone of treatment. However, in cases where these drugs re-
main ineffective, contraindicated, or may cause severe side
effects, other treatment options are desirable [8, 16, 32].
Furthermore, dogs are, unlike humans, unable to verbally
express themselves. Therefore, the true incidence of intoler-
ability to immunosuppressive drugs remains obscure in the
treated animals.
Romiplostim is produced by covalently linking two tan-
dem dimers to the C-terminus of endogenous TPO. Thus,
exposure of cells expressing TPO-R (BaF3-mpl) to
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romiplostim results in rapid tyrosine phosphorylation of
mpl, JAK2, and STAT5, and stimulation of megakaryopoi-
esis and platelet production. Pharmacodynamic studies in
animals including mice, rats, rabbits, monkeys, and dogs
have shown well-tolerability, and dose-dependent in-
creases in platelet counts [24, 27, 33]. Subsequently, well-
designed human studies have been conducted in patients
with chronic ITP. The drug was well-tolerated in all
studies and most events were mild to moderate. Further-
more, there was no evidence of an increased risk of
thromboembolic complications or development of anti-
bodies against natural TPO. In 2008, romiplostim was li-
censed for the treatment of ITP in humans and long-term
treatment appears to be well-tolerable [34–36].
Depending on the phylogenetic differences of TPO-R
in canines and humans, dual usage of TPO-R agonists in
Table 1 Signalment and history of five dogs with primary and secondary immune thrombocytopenia treated with romiplostim
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Table 2 Romiplostim therapy in five dogs with primary and secondary immune thrombocytopenia: Dosage, response and outcome
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both species may be evolutionally encouraging or dis-
couraging. As shown in Fig. 1, TPO-R protein sequences
of canines and humans are very highly conserved at the
C-terminus and the possible binding site for TPO
(EpoR-lig-bind domains) is localised in this highly con-
served area. As romiplostim interacts with an extracellu-
larly located part of TPO-R and canine and human
protein sequences are highly conserved, this may be the
molecular basis of this therapeutic effect in canine ITP.
Consistently, the safety and haematological efficiency of
recombinant human TPO peptide has been demon-
strated in chemotherapy-induced thrombocytopenia in
dogs [37]. To date, two TPO-R agonists, romiplostim
and eltrombopag, have been approved by the FDA for
the treatment of ITP in humans. Although both of these
drugs activate TPO-R and are used for the same indica-
tions, their binding properties and their mode of action
in activating TPO-R is rather different. In contrast to
romiplostim, eltrombopag interacts with the transmem-
brane domain of TPO-R, where the protein sequences
are not phylogenetically highly conserved. Therefore, we
preferred to use romiplostim as a potential candidate
drug for the treatment of ITP in dogs.
In this observational study, we treated five dogs with
ITP with romiplostim. All five dogs appeared not only to
tolerate the drug quite well, but four of the five dogs also
responded relatively quickly with a significant increase
of platelet counts. One dog with secondary ITP that had
not responded to prednisolone and romiplostim at a
dosage of 5 μg/kg responded to a higher dosage of romi-
plostim. Based on the dogs’ medical history, the increase
of platelet counts did not appear to be related to con-
comitant treatment with prednisolone.
One limitation of this pilot study is the low sample
size and the inclusion of primary and secondary ITP
forms. In some cases, contaminant immunosuppressive
drugs was also necessary, at least, at the beginning of
romiplostim therapy. Because of these limitations, dogs
were treated with individual therapy protocol, inside of a
clinical trial set-up. Depend on the duration of response,
length of treatments were also varying for each individ-
ual dog. We report here a mean length of treatment of
13.8 weeks, whereas a mean treatment duration in hu-
man has been recently reported as 60 weeks and a max-
imum duration of 96 weeks [38]. Romiplostim dosage
was reduced in 4 dogs (information is given in Table 2,
Fig. 1 Multiple sequence analysis of thrombopoietin receptor protein sequences in canines and humans. a Conserved domains on the
human thrombopoietin receptor gi|730980|sp|P40238.1|TPOR_HUMAN; b Conserved domains on the canine thrombopoietin receptor
gi|73978050|ref|XP_853442.1|Canis lupus familiaris; c Protein sequence alignments of conserved Erythropoietin receptor, ligand binding (EpoR-lig-bind)
domains in extracellular part of canines and human thrombopoietin receptor (MPL)
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initial dose – maintenance dose). In 3 cases romiplostim
was given until the end of the observation period, one
case (no. 3) was euthanized, case no. 5 was lost for
follow-up.
Interestingly, the start of the increase in platelets in
treated dogs appears to occur within two days after the
first administration. The question whether this effect
would be faster via the administration of higher doses,
i.e. initially 10 μg/kg, remains to be answered in future
studies. If this assumption would be true, romiplostim
would be indicated as a first-line therapy in dogs requir-
ing emergency treatment, i.e. dogs with life-threatening
bleeding. The question why romiplostim appears to in-
crease platelet counts in dogs faster than in humans re-
mains obscure.
Romiplostim and other TPOs such as eltrombopag
represent a new therapeutic measure for ITP in dogs
that cannot be treated with conventional drugs or where
these drugs are ineffective. Interestingly, the rapid effect
is comparable with that observed in dogs treated with
vincristine or IVIgG [18, 19].
Availability of romiplostim for usage in veterinary
medicine may be limited by its high cost. We would
therefore like to highlight one possible solution. The re-
quired amount of romiplostim for each human patient is
dependent on the patient’s response and is extremely
variable. Some patients may require less than 100 μg,
while others may require > 500 μg. Since the drug is only
available in 250 μg and 500 μg vials, it cannot be avoided
that the rest of the drug will be discarded. Based on our
experience, the rest of the dissolved romiplostim can be
stored for several weeks (6–8 weeks) under sterile condi-
tions at 4 ° C without a dramatic loss in biological activ-
ity. On the other hand, dogs need in total less amounts
of the drug than humans. Thus, the available vials might
be used in parallel for treatment of three or more dogs
at the same time.
We presented here the results of a pilot study and
showed that the approved human drug romiplostim may
represent a novel therapeutic option in refractory dog
ITP.
Conclusions
Romiplostim is effective in the treatment of ITP in dogs
at least as well as in humans. This finding may help to
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